Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07205887) titled 'A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: EyeBiotech Ltd.
Condition:
Neovascular Age-Related Macular Degeneration (NVAMD)
Branch Retinal Vein Occlusion (BRVO)
Intervention:
Drug: EYE103
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: September 12, 2025
Target Sample Size: 160
C...